Please login to the form below

Not currently logged in
Email:
Password:

suptavumab

This page shows the latest suptavumab news and features for those working in and with pharma, biotech and healthcare.

US, EU regulators back rapid reviews of AZ’s RSV med

US, EU regulators back rapid reviews of AZ’s RSV med

Another rival, Regeneron’s antibody suptavumab (REGN2222), was dropped from development in 2017 after a late-stage trial failure.

Latest news

  • AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

    The prospects for both of AZ’s drugs for RSV prevention took an upturn last year, when a potential rival – Regeneron’s suptavumab – was dropped from development after missing its targets

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    This is the second pipeline disappointment for Regeneron in recent months after it abandoned respiratory syncytial virus (RSV) candidate suptavumab, which failed to hit the mark in a phase III trial

  • Regeneron drops RSV drug Regeneron drops RSV drug

    Suptavumab failed to prevent the infections in re-term infants. Regeneron has said it will end the development of its late-stage candidate for the prevention of respiratory syncytial virus (RSV) ... infection. The trial enrolled 1, 149 infants who were

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...